Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Hypertensive male participant between 18 to 55 years of age for Panels A to D; hypertensive male or female of non-childbearing potential between 65 to 80 years of age for Panels E and F; healthy males between 18 to 55 years of age for Panel G; hypertensive male or non-childbearing potential female between 18 to 65 years of age (inclusive) for Panel H; hypertensive male between 18 to 65 years of age for Panels I and J~* Body Mass Index (BMI) ≤ 33 kg/m\^2~* In good age appropriate health~* No history of clinically significant cardiac disease~* Nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months~Exclusion Criteria:~* Mentally or legally incapacitated, has significant emotional problems or has a history of a clinically significant psychiatric disorder over the last 5 years~* History of stroke, chronic seizures, or a relevant major neurological disorder~* History of neoplastic disease (cancer)~* Unable to refrain from or anticipates the use of any medication, including any non-steroidal anti-inflammatory drug (NSAID) and aspirin-containing products, prescription and non-prescription drugs or herbal remedies for 2 weeks prior to study start up to end of study~* Anticipates using erectile dysfunction medications during the study~* Uses or anticipates using organic nitrates during the course of the study (e.g. nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, pentaerythritol)~* Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 mL/10 ounces\], wine \[125 mL/4 ounces\], or distilled spirits \[25 mL/1 ounce\]) per day~* Has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 4 weeks~* History of significant multiple and/or severe allergies (including latex allergy)~* Current regular user (including recreational use) of any illicit drugs or has a history of drug (including alcohol) abuse within approximately 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Panel A: Mild/Moderate Hypertension (Type: EXPERIMENTAL): MK-8150 or matching placebo once daily, capsules, oral, for 10 days
- Panel B: Mild/Moderate Hypertension (Type: EXPERIMENTAL): MK-8150 or matching placebo once daily, capsules, oral, for 10 days
- Panel C: Mild/Moderate Hypertension (Type: EXPERIMENTAL): MK-8150 or matching placebo once daily, capsules, oral, for 10 days
- Panel D: Mild/Moderate Hypertension (Type: EXPERIMENTAL): MK-8150 or matching placebo once daily, capsules, oral, for 10 days
- Panel E-Elderly (Type: EXPERIMENTAL): Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
- Panel F - Elderly (Type: EXPERIMENTAL): Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
- Panel G - Healthy - Dose Titration (Type: EXPERIMENTAL): MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
- Panel H - Crossover (Type: EXPERIMENTAL): MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
- Panel I - Dose Titration (Type: EXPERIMENTAL): MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
- Panel J - Dose Titration (Type: EXPERIMENTAL): MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.

Based on this trial design, predict the completion outcome and termination type (if applicable).